Disc Medicine to Participate in Upcoming Investor Conferences
Disc Medicine (NASDAQ:IRON) announced that company management will participate in fireside chats at three investor conferences in November 2025.
Events and times:
- Guggenheim Second Annual Healthcare Innovation Conference — Monday, November 10, 2025 at 4:30 p.m. ET
- Stifel 2025 Healthcare Conference — Thursday, November 13, 2025 at 8:40 a.m. ET
- Jefferies London Healthcare Conference — Wednesday, November 19, 2025 at 2:00 p.m. GMT
Disc Medicine (NASDAQ:IRON) ha annunciato che la direzione della società parteciperà a colloqui informali (fireside chats) in tre conferenze per investitori a novembre 2025.
Eventi e orari:
- Guggenheim Second Annual Healthcare Innovation Conference — Lunedì 10 novembre 2025 alle 16:30 ora ET
- Stifel 2025 Healthcare Conference — Giovedì 13 novembre 2025 alle 8:40 ET
- Jefferies London Healthcare Conference — Mercoledì 19 novembre 2025 alle 14:00 GMT
Disc Medicine (NASDAQ:IRON) anunció que la dirección de la empresa participará en charlas junto a la chimenea (fireside chats) en tres conferencias para inversores en noviembre de 2025.
Eventos y horarios:
- Guggenheim Second Annual Healthcare Innovation Conference — Lunes, 10 de noviembre de 2025 a las 4:30 p. m. ET
- Stifel 2025 Healthcare Conference — Jueves, 13 de noviembre de 2025 a las 8:40 a. m. ET
- Jefferies London Healthcare Conference — Miércoles, 19 de noviembre de 2025 a las 2:00 p. m. GMT
Disc Medicine (NASDAQ:IRON)는 2025년 11월에 열리는 세 곳의 투자자 컨퍼런스에서 회사 경영진이 파이어사이드 챗에 참여할 것이라고 발표했습니다.
이벤트 및 시간:
- Guggenheim 제2회 연례 헬스케어 혁신 컨퍼런스 — 2025년 11월 10일 월요일 오후 4시 30분 동부표준시
- Stifel 2025 헬스케어 컨퍼런스 — 2025년 11월 13일 수요일 오전 8시 40분 동부표준시
- Jefferies London 헬스케어 컨퍼런스 — 2025년 11월 19일 수요일 오후 2시 GMT
Disc Medicine (NASDAQ:IRON) a annoncé que la direction de l’entreprise participera à des entretiens informels (fireside chats) lors de trois conférences pour investisseurs en novembre 2025.
Événements et heures :
- Guggenheim Second Annual Healthcare Innovation Conference — Lundi 10 novembre 2025 à 16h30 ET
- Stifel 2025 Healthcare Conference — Jeudi 13 novembre 2025 à 8h40 ET
- Jefferies London Healthcare Conference — Mercredi 19 novembre 2025 à 14h00 GMT
Disc Medicine (NASDAQ:IRON) gab bekannt, dass das Unternehmensmanagement an Fireside-Chats bei drei Investorenkonferenzen im November 2025 teilnehmen wird.
Veranstaltungen und Zeiten:
- Guggenheim Second Annual Healthcare Innovation Conference — Montag, 10. November 2025 um 16:30 Uhr ET
- Stifel 2025 Healthcare Conference — Donnerstag, 13. November 2025 um 8:40 Uhr ET
- Jefferies London Healthcare Conference — Mittwoch, 19. November 2025 um 14:00 GMT
Disc Medicine (NASDAQ:IRON) أعلنت إدارة الشركة أنها ستشارك في دردشات Fireside عند ثلاث مؤتمرات للمستثمرين في نوفمبر 2025.
الفعاليات والمواعيد:
- Guggenheim Conference على هامش الابتكار في الرعاية الصحية السنوية الثانية — الإثنين 10 نوفمبر 2025 الساعة 4:30 مساءً بتوقيت شرق الولايات
- Stifel مؤتمر الرعاية الصحية 2025 — الخميس 13 نوفمبر 2025 الساعة 8:40 صباحاً بتوقيت شرق الولايات
- Jefferies London Conference للرعاية الصحية — الأربعاء 19 نوفمبر 2025 الساعة 2:00 مساءً بتوقيت GMT
- None.
- None.
WATERTOWN, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in fireside chats at three upcoming investor conferences:
- Guggenheim Second Annual Healthcare Innovation Conference on Monday, November 10th at 4:30 p.m. ET.
- Stifel 2025 Healthcare Conference on Thursday, November 13th at 8:40 a.m. ET.
- Jefferies London Healthcare Conference on Wednesday, November 19th at 2:00 p.m. GMT.
Live webcasts of the fireside chats will be available through the investor relations section of the Company's website at ir.discmedicine.com and an archived replay will be available after each event.
About Disc Medicine
Disc Medicine (NASDAQ:IRON) is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit www.discmedicine.com.
Media Contact
Peg Rusconi
Deerfield Group
peg.rusconi@deerfieldgroup.com
Investor Relations Contact
Christina Tartaglia
Precision AQ
christina.tartaglia@precisionaq.com